Centreville Bank, a nearly 200-year-old mutual bank with $3 billion in assets, has chosen Jack Henry's technology to support its growth and modernization efforts. The bank will implement Jack Henry's cloud-based core processing platform and integrated solutions like the Banno Digital Platform and JHA Treasury Management to enhance digital banking and cash management services. This move aims to improve customer and employee experience, automate workflows, and expand capabilities across Rhode Island and Connecticut. The partnership reflects Centreville Bank's commitment to innovation and community-focused banking as it approaches its bicentennial anniversary.
Centreville Bank's recent technology partnership is presented here with Financials-sector market data from Pluang as of Sep 21, 2026 18:51 WIB. For readers following Financials, of 82 priced US stocks tradable on Pluang, 61 rose and 10 fell today. Notable movers include CLSK at USD 15.08 with a 1-day change of +4.22%, BTBT at USD 1.78 with +2.89%, and BCS at USD 25.55 with +2.73%.
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Faruqi & Faruqi, LLP is investigating claims against Ardelyx for allegedly misleading investors about the commercial performance of its drugs XPHOZAH and IBSRELA. The lawsuit alleges Ardelyx failed to disclose increasing payer restrictions that hurt ...
